Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Andarine (S-4)

Our opinion on this compoundEstablished workhorse

26/100

Superseded prototype SARM with abandoned clinical development and narrow SAR probe utility

Yeah, andarine is historically important and practically irrelevant for most serious research programs right now. It’s the structural parent of the entire aryl propionamide SARM lineage, GTx-007, the compound Dalton’s group at the University of Tennessee used to establish the SARM concept before they handed the baton to ostarine and moved on. That lineage story is genuinely interesting. The compound itself is not.

Here’s the problem: andarine was superseded by its own derivative. Ostarine (enobosarm, GTx-024) exists specifically because S-4’s clinical development hit a wall in the form of that dose-dependent visual disturbance, the yellow-green color tint that appears around 50 mg and above. The mechanism appears to involve non-AR-mediated binding to retinal photoreceptor proteins, and while it reverses on discontinuation, it was clinically unacceptable for any chronic-use indication. GTx didnt abandon S-4 because the AR biology was wrong. They abandoned it because a structurally similar compound without the retinal liability was sitting in the pipeline. That’s not a research compound’s origin story you want to build a program around.

The SARM mechanism itself, tissue-selective AR partial agonism through the propionamide scaffold, is now mature pharmacology. The class has moved past andarine in every meaningful direction. Ostarine went to phase 3 in cancer cachexia and muscle wasting. LGD-4033 has published human PK data. RAD-140 has brain-penetrant properties that open a different set of questions entirely. Andarine is the structural ancestor of all of them, but ancestry doesn’t translate into research utility in 2026.

What we’d actually grant it: the retinal side effect is genuinely undercharacterized. The non-AR mechanism behind the photoreceptor binding is an open question, and if someone wanted to probe SARM off-target effects in visual tissue or build an in vitro assay for retinal safety screening in novel androgen modulators, S-4 is the natural tool. Thats a real research niche. The compound also has reference value in aryl propionamide SAR panels, where having the original scaffold in the comparison set makes mechanistic sense.

But those uses are narrow and specialized. The compound has thin preclinical depth outside the original Dalton program, essentially no clinical data of its own, and competes directly against ostarine in any application where you’d actually want an aryl propionamide SARM. For most research programs, andarine is a historical footnote kept in the library for completeness and lineage documentation. We dont expect it to drive a serious research agenda, and the score reflects that honestly.

Novelty

22

Mechanism promise

28

In-category differentiation

20

Evidence quality

30

Translational signal

22

Research bench value

45

Rationale Andarine scores low primarily because it was actively superseded by its own structural derivative (ostarine) and clinical development was abandoned due to retinal tolerability failure rather than mechanism failure; the aryl propionamide SARM mechanism is now decades-old pharmacology, and the compound has essentially no clinical data and limited research utility beyond SAR reference work and the undercharacterized photoreceptor side effect.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective androgen receptor modulator (early-generation)

An early-generation aryl propionamide SARM; the structural lineage compound from which ostarine was derived.

Abstract

Andarine (S-4, GTx-007; CAS 401900-40-1; molecular formula C19H18F3N3O6; molecular weight 441.36) is a non-steroidal aryl propionamide SARM developed by Dalton and colleagues at the University of Tennessee, the structural precursor to ostarine. The compound exhibits tissue-selective AR agonism and demonstrated efficacy in osteoporosis and BPH preclinical models. Notable for a dose-dependent visual side effect: yellow-green tint to vision at doses above approximately 50 mg, attributed to non-AR-mediated effects on retinal photoreceptors and pigments. The visual effect is reversible on discontinuation but proved clinically unacceptable for long-term development; GTx redirected development to ostarine for superior tolerability. Andarine retains research utility as the prototype aryl propionamide SARM and is widely used recreationally despite no regulatory approval. Plasma half-life is approximately 4 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-264Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Triptorelin

Plain-language summaryIntrigue 55 / 100

Triptorelin (Trelstar) is a synthetic 10-amino-acid GnRH agonist used in long-acting depot form for prostate cancer, endometriosis, and precocious puberty. The pharmacology has a counterintuitive twist: continuous (rather than the normal pulsatile) GnRH receptor stimulation initially causes a flare in testosterone or estrogen, then desensitizes and downregulates the receptor over one to two weeks, producing sustained suppression. So a drug that activates the GnRH system ends up shutting down sex hormone production. The depot formulations release peptide over one, three, or six months. In bodybuilding circles a single-shot dose has been used (anecdotally and unwisely) as post-cycle therapy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Mature FDA-approved GnRH agonist with solid evidence but negligible novelty in a crowded class

Look, triptorelin is a competent, well-characterized clinical tool that does exactly what it says it does. The pharmacology here is about as settled as pharmacology gets: flood the pituitary GnRH receptors continuously, desensitize and downregulate them, and you get medical castration. That mechanism was worked out decades before the 2000 FDA approval of Trelstar, and theres nothing particularly surprising left to find in it. This is not a criticism of the compound as a drug. It’s a criticism of the compound as a research frontier.

The GnRH agonist class is genuinely crowded. Leuprolide has dominated the space since the 1980s and remains the reference standard in most academic endocrine pharmacology labs. Goserelin and histrelin fill the same niche. Triptorelin competes on depot formulation options and a slightly differentiated approval profile, but it isnt best-in-class on any dimension that would give a bench scientist a reason to reach for it specifically over its peers. If your question requires a GnRH agonist probe, you probably already have a protocol built around leuprolide.

What we do credit: the evidence base is real. Multiple phase 3 RCTs across prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. Well-replicated mechanism, clean PK data across depot formulations (1-month, 3-month, 6-month), and a regulatory record that spans more than two decades. The translational signal is unambiguous. This is a compound that works in humans on its stated targets. Thats worth something, even if it doesn’t generate novel research questions.

Honestly, the scenario where triptorelin earns a slot in a serious research program is fairly narrow: HPG axis suppression as a model condition for studying downstream hormone-dependent biology, testosterone flare characterization in oncology models, or comparative GnRH receptor desensitization kinetics. For those questions, its a legitimate tool. But for investigators looking for compounds that open new mechanistic territory or generate the kind of data that moves a field, triptorelin doesnt offer that. The interesting GnRH biology is increasingly happening in the GnRH antagonist space (degarelix, relugolix) and in the kisspeptin-neurokinin signaling layer upstream of the receptor. Triptorelin sits downstream of that action and well behind the frontier.

We keep it in the library as a reference-grade GnRH agonist with documented PK and a clean regulatory trail. What we don’t think is that a researcher picking this up today is likely to find something new. The territory has been mapped.

Novelty

20

Mechanism promise

28

In-category differentiation

25

Evidence quality

78

Translational signal

72

Research bench value

42

Rationale Triptorelin’s high evidence and translational scores reflect genuine regulatory validation and well-replicated clinical outcomes across four approved indications, but those gains are largely cancelled by rock-bottom novelty (1970s chemistry, mechanism textbook-complete) and weak differentiation in a class that includes leuprolide, goserelin, and histrelin. Bench value exists but is constrained by the availability of interchangeable GnRH agonist reference tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic GnRH agonist (decapeptide)

A synthetic GnRH agonist decapeptide used for paradoxical HPG suppression in prostate cancer, endometriosis, and precocious puberty.

Abstract

Triptorelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; CAS 57773-63-4; molecular formula C64H82N18O13; molecular weight 1311.45) is a synthetic GnRH (LHRH) agonist decapeptide developed in the 1970s and approved by the FDA in 2000 (Trelstar). Mechanism: continuous occupation of pituitary GnRH receptors initially produces a flare in LH, FSH, and consequent sex hormone secretion (1 to 2 weeks); chronic exposure desensitizes and downregulates GnRH receptors, producing a sustained reduction in LH and FSH and, downstream, in testosterone (men) and estradiol (women). Plasma half-life of the parent peptide is approximately 3 hours; depot formulations release peptide over 1, 3, or 6 months for sustained suppression. Approved indications include locally advanced and metastatic prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. The flare period in prostate cancer is mitigated by concurrent androgen receptor antagonist (bicalutamide). Used as a reference GnRH agonist in academic endocrine pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-282Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Bromocriptine

Plain-language summaryIntrigue 58 / 100

Bromocriptine is a semi-synthetic ergot alkaloid (chemically descended from a fungus that grows on rye) that activates D2 dopamine receptors. It was the first dopamine agonist used for Parkinson disease and remains the standard treatment for prolactin-secreting pituitary tumors, where it shrinks the tumor and normalizes hormone levels. It also has off-label uses in type 2 diabetes (a quick-release morning formulation called Cycloset improves glucose control through hypothalamic dopamine signaling) and has been investigated for obesity. Long-term ergot exposure carries cardiac valve and lung scarring risk, which has shifted prescribing toward newer non-ergot alternatives like pramipexole. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature D2 agonist with an interesting circadian-metabolic angle, largely superseded in its original indications

Bromocriptine is a 1978 approval that’s had a genuinely interesting second act, but the honest read is that it’s a mature compound navigating three different indication spaces and either been supplanted or remains a minor player in each of them.

The core mechanism is D2 dopamine agonism, with secondary D1, alpha-adrenergic, and serotonergic activity. In Parkinson disease it was largely replaced by cleaner non-ergot agonists like pramipexole and ropinirole, which carry fewer fibrotic and ergot-class side effects. In prolactinoma, cabergoline has better receptor selectivity and tolerability. The original indications are not where the interesting research is.

The Cycloset story is more compelling. The circadian dopaminergic hypothesis holds that the morning dopamine peak in the SCN-hypothalamic axis sets metabolic state, and that resetting this rhythm with a timed-release D2 agonist can improve insulin sensitivity independent of weight or direct insulin-pathway intervention. That’s a genuinely different angle than every other T2D mechanism in the current pharmacopeia. The CYCLOSET Safety Trial and supporting work showed real HbA1c reductions, though effect sizes are modest compared to GLP-1 receptor agonists. What we find interesting is less the effect size and more the mechanism: it implies a neuroendocrine-metabolic interface that’s still undercharacterized, and bromocriptine is currently the only approved probe for it in a metabolic context.

The evidence base is solid in the aggregate. Decades of clinical use, FDA approval across multiple indications, and the 2009 Cycloset approval came with actual phase 3 data. Translational signal is real but not dramatic: it works, in modest ways, across multiple systems. Evidence quality and translational signal are the highest-scoring axes here, and they hold the overall up.

Where bromocriptine loses points is novelty and differentiation. Theres not much open research territory. The compound is fully characterized, the pharmacokinetics are understood, and the major clinical questions have been answered. Researchers working on dopamine receptor pharmacology still use it as a reference agonist, which gives it modest bench value, but its not shaping the questions being asked. Investigators in the circadian-metabolic space might pull it as a probe, but we’d want to see more replication of the central SCN-metabolic hypothesis before calling it a priority tool.

The overall picture: a well-documented compound with a mildly interesting metabolic angle, clear real-world effects, and limited research upside for anyone not specifically working the circadian-dopamine-metabolic axis. Not junk. Just not the frontier.

Novelty

20

Mechanism promise

40

In-category differentiation

42

Evidence quality

75

Translational signal

67

Research bench value

52

Rationale Bromocriptine scores well on evidence quality (multi-decade clinical literature, two separate FDA approvals) and translational signal, but novelty is low for a 1978 compound and differentiation is weak since it has been supplanted by cleaner agents in both Parkinson and prolactinoma. The Cycloset circadian-dopamine metabolic mechanism is the only genuinely interesting current research angle, and it elevates mechanism and bench value modestly, but not enough to move the overall meaningfully.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ergoline D2 dopamine receptor agonist

An ergoline-derived D2 receptor agonist; used in Parkinson disease, prolactinoma, and (off-label) for diabetes and obesity research.

Abstract

Bromocriptine (2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-alpha-(2-methylpropyl)ergotaman-3′,6′,18-trione; CAS 25614-03-3; molecular formula C32H40BrN5O5; molecular weight 654.59) is a semi-synthetic ergoline derivative developed at Sandoz and approved by the FDA in 1978 (Parlodel) for Parkinson disease and hyperprolactinemia. The compound is a high-affinity D2 dopamine receptor agonist (Ki approximately 5 nM) with secondary D1, alpha-adrenergic, and serotonergic effects. The dopaminergic activity in pituitary lactotrophs suppresses prolactin secretion (the prolactinoma indication); the activity in basal ganglia provides modest symptomatic relief in Parkinson disease (largely supplanted by levodopa and non-ergot agonists). A formulation released in the morning (Cycloset, FDA approved 2009) is approved for type 2 diabetes; the rationale is reset of the circadian dopaminergic peak and consequent metabolic improvement. Plasma half-life is 4 to 6 hours; metabolism is hepatic via CYP3A4. Used as a reference D2 agonist with broad receptor profile.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-315Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cutamesine (SA-4503)

Our opinion on this compoundNiche research probe

54/100

Cleanest sigma-1 probe available; real bench utility but modest and mixed clinical results keep the ceiling low

Look, sigma-1 is genuinely interesting biology. It’s not a traditional receptor. It’s a chaperone protein sitting at the mitochondria-associated ER membrane, regulating IP3 receptors, calcium transfer between organelles, and cellular stress responses. When a compound engages sigma-1, you’re not turning a GPCR on or off. You’re modulating a protein that helps the cell manage ER stress and mitochondrial calcium homeostasis. Thats a different kind of pharmacology, and it opens angles that conventional receptor agonism doesn’t reach.

SA-4503 is the cleanest tool you can buy for studying that biology. Ki of roughly 17 nM at sigma-1 with greater than 100-fold selectivity over sigma-2, and minimal off-target binding beyond that. Most sigma-1 ligands are messy. Fluvoxamine hits sigma-1 but it’s primarily an SSRI, so you can’t attribute any effect cleanly. PRE-084 has been used in academic labs but SA-4503 has become the canonical reference compound precisely because the selectivity story is tight. If your hypothesis is sigma-1 mediated, this is the compound you need to run it cleanly.

Here’s the thing: the clinical picture muddies the enthusiasm considerably. The phase 2 ischemic stroke trial (60 mg, starting within 72 hours, 28 days) showed modest improvement. The MDD phase 2 results were mixed. We don’t see the kind of signal here that makes an investigator want to restructure a research program around the target. Sigma-1’s role in neuroprotection has generated decades of preclinical work and the bench-to-clinic arrow is weaker than the mechanistic story implies. That gap is real and honestly we don’t have a clean explanation for it yet.

What keeps the score from dropping further is exactly that bench utility. Sigma-1 has been pulled into COVID-19 biology (the virus binds sigma-1 through the ORF9c protein), neurodegeneration, addiction circuits, and pain processing. If you’re running any of those programs and you want a clean pharmacological probe to dissect sigma-1 contribution, SA-4503 is irreplaceable. It’s not that the compound is exciting in the way that a novel triple agonist or a mitochondrial peptide is exciting. It’s that for a specific class of research questions, its the only rigorous tool.

We think this lands firmly in niche-probe territory. Dont buy it unless sigma-1 is already in your hypothesis. If it is, dont buy anything else.

Novelty

40

Mechanism promise

60

In-category differentiation

68

Evidence quality

50

Translational signal

38

Research bench value

72

Rationale SA-4503 scores primarily on differentiation and bench value: it’s the canonical selective sigma-1 agonist and nothing else comes close on selectivity, which matters if you’re running a sigma-1 program. But the sigma-1 story is decades old, phase 2 results in both stroke and MDD were modest to mixed, and the indication space is specialized enough that most investigators won’t touch it unless sigma-1 is already in their hypothesis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective sigma-1 receptor agonist

A selective sigma-1 receptor agonist developed for ischemic stroke recovery and major depressive disorder.

Abstract

Cutamesine (SA-4503; CAS 165377-44-6; molecular formula C19H30N2O2; molecular weight 318.45) is a selective sigma-1 receptor agonist developed at Santen Pharmaceutical and licensed to M’s Science. The compound has high sigma-1 affinity (Ki approximately 17 nM) with greater than 100-fold selectivity over sigma-2 and minimal off-target binding. Sigma-1 is a chaperone protein at the mitochondria-associated ER membrane that modulates ion channels, calcium signaling, and stress response. Phase 2 trials in ischemic stroke recovery (60 mg, 28 days starting within 72 hours of stroke) showed modest improvement; phase 2 in MDD showed mixed efficacy. Plasma half-life is approximately 5 hours. The compound is the cleanest available research probe for sigma-1 pharmacology. Used as the canonical selective sigma-1 agonist in academic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-332Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tramadol

Plain-language summaryIntrigue 56 / 100

Tramadol, sold as Ultram, is an atypical opioid analgesic that combines weak direct mu-opioid receptor binding with serotonin and norepinephrine reuptake inhibition (the SNRI mechanism shared with antidepressants). The opioid effect comes mostly from a metabolite called M1, generated by the CYP2D6 liver enzyme, which means CYP2D6 ultra-rapid metabolizers (about 7 percent of Caucasians, higher in some other populations) get dramatic opioid effects from standard doses. The dual mechanism creates two distinct hazards: opioid dependence and serotonin syndrome when combined with SSRIs or other serotonergic drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Mature atypical opioid fully characterized; canonical reference compound with no active frontier research angle

Look, tramadol is about as thoroughly characterized as a drug gets. Developed at Grunenthal in the 1970s, FDA approved in 1995 as Ultram, and then rescheduled to Schedule IV in 2014 after accumulating abuse data. The dual mechanism (weak mu-opioid receptor agonism plus serotonin-norepinephrine reuptake inhibition) was genuinely interesting when first described. Thats not 2026.

The pharmacology is textbook at this point. The parent compound has modest mu-opioid affinity (Ki around 2 microM), and the real opioid activity comes from CYP2D6-mediated conversion to O-desmethyltramadol (M1), which sits roughly 200-fold higher in receptor affinity. The SNRI component contributes to the analgesic profile but also creates the serotonin syndrome risk that makes combination use genuinely dangerous. SERT Ki around 1 microM, NET Ki around 0.4 microM. None of this is contested. None of it is novel. It’s the kind of mechanism that gets a single textbook paragraph and stays there.

Where tramadol does earn its keep is as a reference compound for specific mechanistic work. CYP2D6 pharmacogenomics researchers use it as a clean model for prodrug activation studies, given how neatly M1 formation maps to metabolizer phenotype. Serotonin syndrome risk modeling uses tramadol as a canonical dual-mechanism case when probing drug-drug interaction space. That’s real value, and we credit it. But it’s narrow, and those aren’t frontier questions.

The evidence base is actually quite solid relative to a lot of what’s in the library. Decades of clinical PK/PD data, well-replicated across diverse populations, good pharmacogenomic characterization of poor versus ultrarapid CYP2D6 metabolizer outcomes. Evidence quality isn’t the limiting factor here. The issue is that all that evidence has already answered the questions it was built to answer.

We don’t see an emerging research angle that would push tramadol back onto a serious investigator’s priority list. It’s not being repurposed for a novel indication with real momentum. It’s not a sharper probe than alternatives for the opioid questions that actually matter right now, things like OPRM1 allosterism, biased agonism at the mu receptor, or opioid-sparing combination mechanisms. The Schedule IV status adds real regulatory friction without any corresponding research upside. If you’re building a program around pain pharmacology, there are cleaner tools for every question tramadol can address. It sits in the library primarily as a reference standard for dual-mechanism analgesic work, and that’s about the ceiling.

Novelty

20

Mechanism promise

30

In-category differentiation

40

Evidence quality

75

Translational signal

70

Research bench value

45

Rationale Evidence quality and translational signal are high (approved drug, decades of replicated clinical PK/PD data), but novelty and mechanism interest are low: 1970s compound, completely characterized pharmacology, no emerging repurposing signal. Bench value is modest but real as a CYP2D6 prodrug model and serotonin syndrome reference case, insufficient to substantially elevate the overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical opioid (mu-opioid + SNRI)

A weak mu-opioid agonist with serotonin-norepinephrine reuptake inhibition; an atypical analgesic with abuse and serotonin syndrome risk.

Abstract

Tramadol ((1R,2R)-rel-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol; CAS 27203-92-5; molecular formula C16H25NO2; molecular weight 263.38) is an atypical opioid analgesic developed at Grunenthal in the 1970s and approved by the FDA in 1995 (Ultram). The compound is a weak mu-opioid receptor agonist (Ki approximately 2 microM, low affinity); the active metabolite O-desmethyltramadol (M1, formed via CYP2D6) has approximately 200-fold higher mu-opioid affinity. Distinct from pure opioids by additional serotonin and norepinephrine reuptake inhibition (SERT Ki approximately 1 microM, NET Ki approximately 0.4 microM), contributing to the analgesic profile and to serotonin syndrome risk when combined with other serotonergic drugs. Plasma half-life is approximately 6 hours; metabolism is via CYP2D6 (M1 production) and CYP3A4. Schedule IV in the US since 2014. The combined opioid and SNRI activity produces seizures (rare at therapeutic doses, more common in overdose), serotonin syndrome (with concurrent serotonergic drugs), and abuse potential intermediate between non-opioid analgesics and full opioids. Used as the canonical atypical opioid in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-348Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Darbepoetin alfa

Plain-language summaryIntrigue 54 / 100

Darbepoetin alfa, sold as Aranesp, is Amgen’s hyperglycosylated EPO analog with two extra sugar chains added to the protein backbone. The added glycosylation extends the plasma half-life from hours to days, supporting once-weekly or once-every-three-weeks dosing instead of three-times-weekly EPO. Mechanism and safety profile are otherwise identical to native EPO, including the same cardiovascular concerns at high doses. Approved in 2001, it is widely used in dialysis units and oncology infusion centers. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

An approved 25-year-old EPO analog with solid PK innovation but minimal research novelty

Look, darbepoetin alfa is exactly what the abstract says it is: native EPO with two extra N-linked glycan chains at positions 30 and 88. That glycoengineering was genuinely impressive when the Amgen team was working it out in the late 1990s, and it produced a drug (Aranesp) that cleared FDA approval in 2001. But thats 25 years ago. The mechanism is JAK2/STAT5 via the EPO receptor, which is about as well-understood as erythropoiesis biology gets, and the pharmacological innovation here is entirely pharmacokinetic, not biological. Half-life runs roughly 25 hours subcutaneous versus 6-13 hours for native EPO; receptor binding affinity is actually about 4-fold lower than epoetin alfa at equimolar doses. You’re not getting new biology. You’re getting a longer dosing window on old biology.

The clinical evidence is solid, and we’ll credit it. Large replicated RCTs support the approved CKD and chemotherapy-induced anemia indications. But the TREAT trial (Pfeffer et al., 2009, NEJM) landed hard: targeting higher hemoglobin in CKD diabetic patients with darbepoetin didn’t improve cardiovascular or renal outcomes and was associated with increased stroke risk. That trial cooled a lot of enthusiasm for ESA optimization and illustrates the ceiling here. The compound works for what it was designed for. Whether that translates to research merit for Kodiac’s library is a different question, and on that axis it’s weaker.

What we like: darbepoetin is the canonical long-acting EPO analog. If you’re running erythropoiesis studies requiring prolonged receptor signaling without serial injections, it’s the obvious tool. There’s also legitimate research interest in non-hematopoietic EPO receptor biology, particularly neuroprotective and cardioprotective signaling arms, where a long-acting form has real probe utility. But the EPOR neuroprotection story has circulated for two decades without decisive human translation, and darbepoetin isn’t the reason for that stall.

The class itself, long-acting ESAs, isn’t a frontier anyone is racing toward right now. The genuinely interesting EPO-adjacent work is in HIF-prolyl hydroxylase inhibitors like roxadustat and daprodustat, which hit the oxygen-sensing pathway upstream and carry a far more novel mechanism. Darbepoetin doesn’t compete there. Its score reflects a compound that performs reliably in its approved niche, but “reliable and approved” is precisely what this rubric is designed NOT to reward.

Novelty

25

Mechanism promise

22

In-category differentiation

45

Evidence quality

75

Translational signal

65

Research bench value

50

Rationale Darbepoetin’s score is held down by low novelty (25-year-old approved drug mechanistically identical to native EPO) and unremarkable biology despite strong clinical evidence; the glycoengineering story is real but the science is now textbook. Its only meaningful edge is as the canonical long-acting EPO tool, though the class has been outpaced by upstream HIF-PH inhibitors for frontier research.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long-acting EPO analog

A hyperglycosylated EPO analog with two additional N-linked glycan chains; extended plasma half-life for less frequent dosing.

Abstract

Darbepoetin alfa (CAS 209810-58-2; modified EPO with two additional N-linked glycosylation sites at amino acid positions 30 and 88; molecular weight approximately 37 kDa) is a hyperglycosylated EPO analog developed at Amgen and approved by the FDA in 2001 (Aranesp). The compound has the same EPO receptor binding mechanism as native EPO but with substantially extended plasma half-life (approximately 25 hours subcutaneous, versus 6 to 13 hours for native EPO) owing to the additional carbohydrate chains slowing renal and hepatic clearance. The receptor binding affinity is approximately 4-fold lower than native EPO at equimolar doses, but the longer half-life produces greater erythropoietic effect per dose. Approved indications match native EPO (CKD anemia, chemotherapy-induced anemia). Used as the canonical long-acting EPO analog in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-364Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Dextroamphetamine

Plain-language summaryIntrigue 65 / 100

Dextroamphetamine is the d-enantiomer of amphetamine, sold as Dexedrine since 1976. The d-form is roughly two to three times more potent at central dopamine release than the l-form, while both release norepinephrine about equally. The practical result is a stimulant tilted toward CNS dopamine effects with somewhat less peripheral cardiovascular load than racemic mixtures like Adderall. Approved for ADHD and narcolepsy. Schedule II. Used clinically when patients tolerate racemic amphetamine poorly and as the canonical pure d-amphetamine reference in research where investigators need to isolate the dopaminergic component of the response. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

41/100

Canonical d-amphetamine reference compound; settled pharmacology, limited frontier value, probe utility only

Dextroamphetamine is about as well-characterized as a compound gets in psychopharmacology. FDA approved in 1976, used clinically for ADHD and narcolepsy for nearly five decades; the literature here is enormous, the mechanism is settled, and the basic pharmacology has been picked over thoroughly. Thats not a knock on the compound: it’s just the reality of its place in the field.

The core story is well-known: d-amphetamine is approximately 2-3x more potent at central dopamine release than the l-enantiomer, while both enantiomers release norepinephrine at roughly equivalent rates. The net pharmacological profile versus racemic amphetamine is a cleaner CNS dopaminergic signal with reduced peripheral sympathomimetic activity. Mechanistically, this is monoamine reverse-transport via DAT, NET, and SERT: textbook amphetamine pharmacology, not something new.

Where it does retain value is as a research probe for pure d-amphetamine pharmacology. If you’re studying enantiomeric contributions to amphetamine effects, comparing d- versus l-amphetamine release dynamics, or using it as a reference standard in translational ADHD models, dextroamphetamine is the canonical compound. There’s no substitute for that specific role. The bench value score reflects this: genuinely useful in a narrow but legitimate context.

What we don’t love is that the interesting amphetamine-adjacent research isn’t really about dextroamphetamine per se anymore. The questions the field actually cares about now involve TAAR1 agonism and its emerging role in monoamine homeostasis, the pharmacogenomics of amphetamine response variability, and dual dopamine-serotonin releasers as novel depression targets. Dextroamphetamine is background context for those conversations, not the interesting variable in them. The differentiation score is modest for good reason: it’s the canonical probe, but the probe itself isn’t what’s being investigated.

Evidence quality is objectively high. This is an approved drug with extensive phase 3 data, multi-decade replication across independent labs, and clear translational signal for ADHD and narcolepsy. But high evidence quality for settled questions doesn’t make a compound compelling as a bench research target; it makes it a reference standard, which is a different thing entirely.

The Schedule II classification adds real logistical friction. DEA licensing, handling requirements, institutional overhead: none of this is insurmountable, but it shapes what a lab is actually going to reach for when designing a study. Combined with the saturation of the literature, there are very few questions a serious bench lab would be trying to answer with dextroamphetamine that haven’t already been answered decades ago. Honestly, it earns its score as a historical anchor and occasional enantiomeric probe; it doesnt earn more than that.

Novelty

10

Mechanism promise

20

In-category differentiation

35

Evidence quality

75

Translational signal

75

Research bench value

55

Rationale Decades-old Schedule II compound with thoroughly settled dopaminergic mechanism; scores high on evidence quality and translational signal for its approved indications but very low on novelty and differentiation, producing a moderate overall that reflects reference-standard status rather than active research frontier. Schedule II cap of 65 does not bind since calculated overall is 41.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

d-enantiomer amphetamine (dopaminergic-preferring)

The d-enantiomer of amphetamine; a more dopaminergic stimulant than the racemic mixture, used in ADHD and narcolepsy.

Abstract

Dextroamphetamine ((S)-1-phenylpropan-2-amine, d-amphetamine; CAS 51-64-9; molecular formula C9H13N; molecular weight 135.21) is the d-enantiomer of amphetamine, approved by the FDA in 1976 (Dexedrine). The d-enantiomer is approximately 2 to 3 fold more potent at central dopamine release than the l-enantiomer; both enantiomers have approximately equivalent norepinephrine release. The pharmacology versus racemic amphetamine is shifted toward CNS dopaminergic effects with reduced peripheral cardiovascular activity. Approved indications: ADHD, narcolepsy. Plasma half-life is approximately 12 hours. Schedule II. Used as the canonical pure d-amphetamine in research and clinical practice for patients tolerating racemic amphetamine poorly.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-380Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Citrulline Malate

Plain-language summaryIntrigue 55 / 100

Citrulline malate combines L-citrulline (an amino acid your kidneys convert into L-arginine) with malic acid (a TCA cycle intermediate). The trick is that citrulline supplementation actually raises blood arginine more effectively than arginine itself, because it bypasses the intestinal arginase enzyme that destroys most oral arginine before it reaches circulation. Higher arginine fuels nitric oxide synthesis (vasodilation, the famous pre-workout pump) and supports urea cycle ammonia clearance. The malate component helps keep TCA-driven ATP production running. Standard pre-workout dosing is 6 to 10 g taken 60 to 90 minutes before exercise, with reasonable evidence for increased resistance training volume and reduced post-workout soreness. Among the more credible pre-workout ingredients. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Well-understood pre-workout ingredient with solid exercise evidence but zero research novelty

Look, citrulline malate is one of those compounds where the science is basically done. The mechanism is completely mapped: L-citrulline converts to L-arginine in the kidneys, bypassing intestinal arginase, which degrades oral arginine before it reaches systemic circulation. That salvaged arginine then feeds nitric oxide synthase, driving vasodilation. The malate portion is a TCA cycle intermediate that supports aerobic ATP production and likely buffers ammonia accumulation during high-intensity work. Clean mechanism, understood for over two decades, nothing surprising here.

The evidence base is actually solid by supplement standards. Multiple RCTs have confirmed effects on resistance training volume, and there’s reasonably consistent data on reduced post-exercise muscle soreness across independent labs. The Perez-Guisado work and subsequent replications are well-documented in exercise physiology. We’re not talking about single-lab work or marketing claims dressed as research. The human translational signal is real and repeatable.

What kills the score is that none of this is interesting anymore. A bench scientist in 2026 is not reaching for citrulline malate as a research target. The NO pathway is saturated territory. The urea cycle angle has been thoroughly mapped. There is no novel indication space, no unexplored mechanism, no surprising biology to chase. The malate contribution specifically is contested: it’s not clear how much malic acid at standard pre-workout doses actually shifts TCA flux in exercising muscle, and the literature hasn’t convincingly resolved whether the 2:1 complex outperforms plain L-citrulline in any meaningful way. Nobody is writing grants to find out.

As a research tool, citrulline malate has essentially no probe value. If you want to study NO biology, you’d reach for L-NAME or well-characterized NOS inhibitors. If you want urea cycle work, there are purpose-built tools. The compound’s entire identity is pre-workout ingredient, and thats not what serious investigators are doing bench work on.

Differentiation is a problem too. The case for citrulline malate over plain L-citrulline rests primarily on industry framing. The malate may contribute something, but evidence that the specific complex has a scientifically meaningful edge over the amino acid alone is thin. You’re stacking two understood, unremarkable metabolites and hoping the combination exceeds the sum.

Honest assessment: this belongs in a sports nutrition product. We stock it because the exercise science is clean and it has utility in protocols where NO pathway manipulation is needed as a straightforward control condition. But it shouldn’t occupy any serious investigator’s attention in 2026.

Novelty

16

Mechanism promise

28

In-category differentiation

25

Evidence quality

58

Translational signal

55

Research bench value

22

Rationale Both L-citrulline and malic acid are fully characterized molecules with mapped pharmacology; the combination has decent RCT support for exercise performance but no novel mechanism, unexplored indication space, or meaningful bench utility to recommend it as a priority research target in 2026.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Amino acid + organic acid (NO precursor / TCA cycle support)

L-citrulline complexed with malic acid; a nitric oxide precursor (via arginine) and TCA cycle substrate used in pre-workout supplements.

Abstract

Citrulline malate (L-citrulline DL-malate, CAS 70796-17-7; complex of L-citrulline (CAS 372-75-8, C6H13N3O3, MW 175.19) and malic acid (CAS 6915-15-7, C4H6O5, MW 134.09); commercial 2:1 or 1:1 ratios) is a complex of the amino acid L-citrulline with malic acid. L-citrulline is converted in the kidneys to L-arginine, the substrate for nitric oxide synthase; circulating arginine produced from citrulline supplementation is paradoxically more effective than direct arginine supplementation owing to the bypass of intestinal arginase. The malic acid portion is a TCA cycle intermediate supporting aerobic ATP production. Combined, the compound improves exercise performance through vasodilation (nitric oxide-mediated), reduced ammonia accumulation (urea cycle support), and ATP production. Plasma half-life of citrulline is approximately 1 hour. Used widely in pre-workout supplements (8 to 10 g doses, 60 to 90 minutes pre-exercise) with documented effects on resistance training volume and reduced post-exercise soreness.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-396Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
CX-614

Plain-language summaryIntrigue 40 / 100

CX-614 is another benzoxazine ampakine in the Cortex series. Investigated in early clinical trials for cognitive impairment. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Potent AMPA probe with real bench utility but no translational path and a stalled class

CX-614 is a benzoxazine ampakine out of the Cortex Pharmaceuticals program that ran through the late 1990s and 2000s alongside CX-516 and CX-546. The compound is legitimately interesting as a probe: its roughly 100-fold potency advantage over CX-516 in AMPA receptor potentiation assays isn’t marketing noise, it shows up consistently in comparative cellular work. If you’re running BDNF induction studies and want pharmacological control over AMPA throughput without saturating concentrations, CX-614 is a real tool.

The BDNF upregulation story is the most compelling part of the science here. Chronic ampakine treatment drives hippocampal BDNF expression through transcriptional mechanisms downstream of AMPA potentiation. This is a legitimate model for studying neurotrophin-mediated synaptic plasticity and it’s been used by multiple independent groups, not just the originating program. That matters. Replication outside Cortex gives the bench utility real credibility and separates CX-614 from single-lab-only probe compounds.

Here’s the thing though: the ampakine class as a therapeutic direction has largely stalled. CX-516 had a small clinical footprint and the results were underwhelming. Seizure risk and excitotoxicity concerns have shadowed every high-potency member of the class. CX-614’s potency, which is an asset on the bench, is a liability from a translational standpoint. That 100-fold number doesnt come with a 100-fold therapeutic window, and there’s no sponsor currently pushing a benzoxazine ampakine through a pipeline.

We dont see a strong path to clinical relevance for CX-614 specifically. The novel angle, AMPA-driven BDNF induction as a tractable route to synaptic plasticity enhancement, remains interesting theoretically, but the pharmacological levers available today include BDNF mimetics, TrkB agonists, and ketamine’s downstream BDNF release mechanism, all of which generate stronger translational signals with more current evidence behind them. The class simply hasn’t rehabilitated itself with more recent data, and CX-614 inherits that problem.

What CX-614 does well is narrow but real: it’s a high-potency probe for dissecting AMPA receptor contributions to BDNF signaling in controlled in vitro and rodent systems. If thats the question you’re asking, honestly, it earns a spot in the toolkit. If you’re looking for a compound that carries a compelling story toward clinical translation or opens a genuinely new mechanistic frontier, there are better candidates right now. The score reflects a compound that occupies a legitimate but limited niche: not junk, not boring, but not the compound you build a program around in 2026.

Novelty

38

Mechanism promise

48

In-category differentiation

45

Evidence quality

42

Translational signal

22

Research bench value

62

Rationale CX-614 earns its place as a legitimate preclinical probe for AMPA-mediated BDNF induction, with multi-lab use validating the bench utility score; however, the ampakine class has largely failed to translate and CX-614 itself has never entered human trials, keeping translational and novelty scores low and pulling the overall to the low 40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Benzoxazine ampakine

A potent benzoxazine ampakine with research applications in BDNF upregulation and synaptic plasticity studies.

Abstract

CX-614 (2H,3H,6aH-pyrrolidino-[2,1-3′,2′]1,3-oxazino-[6′,5′-5,4]benzo[e]1,4-dioxan-10-one; CAS 215923-55-0; molecular formula C16H17NO4; molecular weight 287.32) is a potent benzoxazine-class ampakine developed at Cortex Pharmaceuticals as part of the same program that produced CX-516 and CX-546. CX-614 shows substantially higher AMPA potentiation potency than CX-516 in cellular assays (approximately 100-fold greater per molecule). The compound has been used extensively as a research probe for BDNF upregulation studies; chronic ampakine treatment elevates hippocampal BDNF expression through transcriptional mechanisms downstream of AMPA potentiation, providing a pharmacological model for neurotrophin-mediated synaptic plasticity. CX-614 has not been advanced to human clinical trials. The compound is sold as a research chemical with limited availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-056Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nebracetam

Plain-language summaryIntrigue 30 / 100

Nebracetam is a phenyl-aminomethyl pyrrolidinone racetam developed in Japan. It is reported to enhance acetylcholine release through different mechanisms than other racetams. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Discontinued 1980s racetam with a real M1 twist but no active research community and better probes now available

Look, nebracetam is one of those 1980s Japanese pharma experiments that had a real idea behind it and then got quietly shelved. Daiichi took the piracetam scaffold, dropped a 4-phenyl group onto the pyrrolidinone ring (a structural move similar to phenylpiracetam), and added an aminomethyl modification that introduced something the classical racetams dont have: partial M1 muscarinic acetylcholine receptor agonism. That’s a legitimately different pharmacological profile. M1 selectivity has been a persistent goal in cholinergic CNS pharmacology, and nebracetam gets part of the way there without tipping into the full agonist territory that caused the older M1 programs so much trouble.

The problem is thats where the story peaks. The Phase 2 program in mild cognitive impairment and elderly memory disorders came back positive but modest, and Daiichi discontinued. We dont have a clean public record of exactly why. Was it effect size? A subtle safety signal at scale? Commercial calculus? That ambiguity is itself informative. Nobody has seriously revisited it since, and the absence of follow-on development from any group in four decades is a meaningful data point against it.

The M1 angle would be more compelling if better probes didn’t now exist. Xanomeline-trospium (Cobenfy) has defined what M1 selective agonism can do in a clinical context, and its mechanistic story is sharper than nebracetam’s partial activity. On the racetam side, phenylpiracetam handles the phenyl-substituted question with more accessible literature and a cleaner investigator community behind it. Nebracetam doesnt obviously beat either of those reference compounds on the bench.

The evidence quality is thin relative to its age. The Phase 2 data exists but was never published in a form thats independently verifiable or widely replicated. The Daiichi-era preclinical work is real but aging, and outside replication is sparse enough that this sits close to single-lab territory even though it technically cleared Phase 2. Thats not nothing, but its not a strong foundation for a 2026 research program.

We’d reach for nebracetam only if we were specifically trying to dissect the M1 component of racetam-class effects and had exhausted better options. That’s a narrow historical question. For modern muscarinic research the selective agonist literature is cleaner; for modern racetam research other analogs have more contemporary traction. Honestly, the score reflects its position accurately: interesting concept, real early clinical signal, discontinued program, no serious modern home.

Novelty

22

Mechanism promise

38

In-category differentiation

22

Evidence quality

33

Translational signal

28

Research bench value

25

Rationale Nebracetam has a genuinely distinct profile from classical racetams via partial M1 muscarinic agonist activity, which is the one thing that makes it interesting, but development was discontinued after modest Phase 2 results and no serious external group has picked it up since. Both the muscarinic and the phenyl-racetam questions it was positioned to answer are now better addressed by other compounds.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenyl-substituted aminomethyl pyrrolidinone

A 4-phenyl-pyrrolidinone with M1 muscarinic receptor agonist activity developed by Daiichi for cognitive impairment, discontinued in development.

Abstract

Nebracetam (WEB-1881-FU; 4-phenyl-2-pyrrolidinone-1-acetamide methyl derivative; CAS 97205-34-0; molecular formula C13H18N2O2; molecular weight 234.30) is a piracetam analog developed by Daiichi Pharmaceutical in Japan in the 1980s with structural features distinct from the classical racetam class. The compound includes a 4-phenyl group on the pyrrolidinone ring (similar to phenylpiracetam) and an aminomethyl modification on the acetamide side chain. Pharmacology shows partial M1 muscarinic acetylcholine receptor agonist activity in addition to the cholinergic facilitation typical of the racetam class. Phase 2 trials in mild cognitive impairment and elderly memory disorders showed positive but modest results; the development program was discontinued and the compound was never approved. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled. Pharmacokinetics include plasma half-life of approximately 4 hours and good oral bioavailability. The clinical evidence base is limited; the M1 muscarinic agonist activity introduces a distinct profile from the open-chain racetams.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-038Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 37 38 39 40 41 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.